Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Biomolecules|January 21, 2022
Androgen Receptor as an Emerging Feasible Biomarker for Breast CancerChan-Ping You, Man-Hong Leung, Wai-Chung Tsang, et al.International Journal of Molecular Sciences|December 11, 2022
Modulating the Activity of Androgen Receptor for Treating Breast CancerChan-Ping You, Ho Tsoi, Ellen P S Man, et al.International Journal of Molecular Sciences|June 13, 2025
The Splice Variant of the NCOR2 Gene BQ323636.1 Modulates ACSL4 Expression to Enhance Fatty Acid Metabolism and Support of Tumor Growth in Breast CancerHo Tsoi, Chan-Ping You, Koei Ho-Lam Cheung, et al.Cancers|March 10, 2022
Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast CancerHo Tsoi, Chan-Ping You, Man-Hong Leung, et al.International Journal of Molecular Sciences|October 27, 2022
Checkpoint Kinase 2 Inhibition Can Reverse Tamoxifen Resistance in ER-Positive Breast CancerHo Tsoi, Wai-Chung Tsang, Ellen P S Man, et al.The Journal of Pathology|August 9, 2023
Overexpression of BQ323636.1 contributes to anastrozole resistance in AR+ve/ER+ve breast cancerHo Tsoi, Johann Lok, Ellen Ps Man, et al.Cells|September 13, 2025
BQ323636.1 Employs the AR-CCRK Axis to Modulate the Expression of KU70 to Interfere with Non-Homologous End Joining Mediated DNA Repair MechanismHo Tsoi, Zi-Qing So, Ellen P S Man, et al.Cancers|May 16, 2023
SRSF5 Regulates the Expression of BQ323636.1 to Modulate Tamoxifen Resistance in ER-Positive Breast CancerHo Tsoi, Nicholas Nok-Ching Fung, Ellen P S Man, et al.Journal of Translational Medicine|August 6, 2025
Ivabradine induces RAD51 degradation, potentiating PARP inhibitor efficacy in non-germline BRCA pathogenic variant triple-negative breast cancerHo Tsoi, George Man Hong Leung, Ellen Pui Sum Man, et al.Pageof 1